We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
Offering a more affordable fitness class solution through training small groups and providing unparalleled client care with 1-on-1 personal training sessions. Outrivals has grown rapidly since launching 3 years ago near the famous Old Street Roundabout and are raising funds to open 2 new sites, with plans to have a portfolio of 15 branches over the next 5 years. The company has a high retention rate, with a client life cycle averaging one year.
days to go: Expired investment: £88,450
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £215,946
33Fuel is a natural sports nutrition brand that aims to dominate sports nutrition with healthier and natural alternatives. Its products consist of ingredients like organic flaxseeds, Tibetan goji berries, organic walnuts, and raw coconuts, to name a few. The company has received over 10,000 orders and multiple 5-star customer reviews. It has 12,000 email subscribers and a podcast with more than 65,000 plays. The company wants to dominate the sports nutrition market that is forecast to reach almost £2 billion by 2024. 33Fuel has attracted superstar shareholders including 4x Ironman Triathlon World Champion Chrissie Wellington and customers such as Tour de France winner Sir Bradley Wiggins. The company has won 'Health Product of the Year' and 'Best Meal Replacement' and has featured in fitness and mainstream media such as The Telegraph, Independent, and Men's Fitness. It will use the investment for marketing to accelerate sales.

Pitch Rated

74%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £367,124
Rescape is a company pioneering the use of Virtual Reality (VR) in healthcare and frontline services. Its DR.VR platform, launched in 2019, helped reduce pain and anxiety amongst patients in hospitals and care homes. The company delivers VR content to patients through the Samsung Gear VR headset, a hard-plastic headset, that can be wiped down and disinfected along with VR sanitary eye masks that reduce chances of infection and irritation to patients. Through the company's technology, patients can experience ocean life, amusements parks and relax in some of the most beautiful settings in the world, all from the safety of the healthcare institution. The AR/VR in Healthcare Market is predicted to reach USD 30-40 billion by 2026, and Rescape aims to be a disruptor in this segment. The company will use the investment to grow its business across different verticals.

Pitch Rated

66%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £488,450
The Ticket Bank (TTB) is an online ticketing marketplace that provides event tickets to disadvantaged and marginalised individuals free of charge. The company is powered by 'Tickets for Good'. The company introduced the 'Virtual Ticket Bank' and 'The Giving Back campaign' in the COVID-19 pandemic wherein it is sourcing thousands of tickets for National Health Service (NHS) and frontline care workers to express its gratitude for their services. They can use these tickets when the lockdown is over. TTB has partnered with 20+ theatres including Barbican, Bridge Theatre, and Crucible Theatre, who have agreed on 7,000+ tickets since going to market and onboarded 5,000 new users. It aims to become a contender in a market that is worth £4.7 billion. The company will use the investment to create the integrations and data gathering tools to rapidly grow its channels, as well as, create additional value for both its charity and venue clients.
days to go: Expired investment: £152,653
People spend more on activities for their children than electricity or holidays. KalliKIds makes sure they spend wisely, picking classes, places to go and services they can trust: Trip Advisor or Go Compare for kids with up-front checking. Parents get to know the best choices and discounts and the activity providers get promoted. KalliKids has 670 providers, a renewal rate of >70% and providers signing up for a third year. The website has smashed its five year targets with 27k hits/month.
days to go: Expired investment: £174,946
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph